- Home
- CCJ vs DGX Comparison
CCJ vs DGX Comparison
Compare CCJ & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCJ
- DGX
- Stock Information
- Founded
- CCJ 1987
- DGX 1967
- Country
- CCJ Canada
- DGX United States
- Employees
- CCJ N/A
- DGX N/A
- Industry
- CCJ Other Metals and Minerals
- DGX Medical Specialities
- Sector
- CCJ Basic Materials
- DGX Health Care
- Exchange
- CCJ Nasdaq
- DGX Nasdaq
- Market Cap
- CCJ 21.0B
- DGX 17.5B
- IPO Year
- CCJ N/A
- DGX 1996
- Fundamental
- Price
- CCJ $43.49
- DGX $172.26
- Analyst Decision
- CCJ Strong Buy
- DGX Buy
- Analyst Count
- CCJ 4
- DGX 13
- Target Price
- CCJ $66.56
- DGX $177.69
- AVG Volume (30 Days)
- CCJ 5.1M
- DGX 1.2M
- Earning Date
- CCJ 02-20-2025
- DGX 01-30-2025
- Dividend Yield
- CCJ 0.26%
- DGX 1.86%
- EPS Growth
- CCJ N/A
- DGX 2.67
- EPS
- CCJ 0.27
- DGX 7.69
- Revenue
- CCJ $2,179,375,052.00
- DGX $9,872,000,000.00
- Revenue This Year
- CCJ $16.97
- DGX $10.18
- Revenue Next Year
- CCJ $10.14
- DGX $3.82
- P/E Ratio
- CCJ $158.69
- DGX $22.40
- Revenue Growth
- CCJ 21.18
- DGX 6.70
- 52 Week Low
- CCJ $35.43
- DGX $123.66
- 52 Week High
- CCJ $62.55
- DGX $172.91
- Technical
- Relative Strength Index (RSI)
- CCJ 32.27
- DGX 70.79
- Support Level
- CCJ $45.91
- DGX $166.15
- Resistance Level
- CCJ $48.81
- DGX $172.64
- Average True Range (ATR)
- CCJ 2.00
- DGX 3.27
- MACD
- CCJ -0.44
- DGX 0.74
- Stochastic Oscillator
- CCJ 5.02
- DGX 94.96
About CCJ Cameco Corporation
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. Cameco has three reportable segments, uranium, fuel services and Westinghouse. It derives maximum revenue from Uranium Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia and United States.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.